Earnings Call · Q4 FY2024·2025-02-25

Q4 24EPS +26.44%·Rev n/aQ3 24EPS +39.00%·Rev n/aQ2 24EPS -3.75%·Rev n/aQ1 24EPS +20.80%·Rev n/a⚠ consensus missing

Tarsus Pharmaceuticals, Inc. TARS

David Nakasone — Head of Investor Relations

Bobby Azamian — Chief Executive Officer and Chairman

Aziz Mottiwala — Chief Commercial Officer

Seshadri Neervannan — Chief Scientific Officer

Jeff Farrow — Chief Financial Officer

−9.3%1d on move date−8.8% vs SPY3d−4.4%5d−6.2%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TARS calls or request research access.

More TARS calls Browse calls Request research access